



Seventure's Portfolio Company Santaris Pharma Sold for Up To US \$450m to Roche

Second Exit in Denmark for Seventure

Paris, France – 5 August 2014 – Seventure Partners, one of Europe's leaders in financing innovation, today announces the successful trade sale of Santaris Pharma A/S to Roche for up to \$450 million.

Roche has bought Santaris for an initial \$250 million and will pay an additional \$200 million if Santaris meets certain development milestones.

Santaris Pharma is a Danish biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. Seventure has invested in the company since 2007 and has participated in all subsequent rounds.

Pantheo A/S and Cureon A/S merged in 2003 to create Santaris A/S, which developed specialised antisense therapeutics technology based on its proprietary Locked Nucleic Acid (LNA) chemistry platform. Santaris Pharma has developed a diverse pipeline of drug candidates for both rare and common diseases and has established strategic partnerships with Hoffmann-La Roche, Bristol-Myers Squibb, Shire PLC, Pfizer, GlaxoSmithKline, miRagen Therapeutics, RaNa Therapeutics Inc. and Isarna Therapeutics GmbH.

Isabelle de Cremoux, President and Managing Partner at Seventure Partners, said: "We are a world leader in financing innovations in the converging domains of medicine and food. This successful exit further adds to our track record of international investment and our high selection standards. As the only French VC firm invested in Santaris, this investment also reflects our strong relationships and presence in Denmark with the local investment, research and business communities."

The sale of Santaris is the second exit of a portfolio company in Denmark for Seventure, following the sale of Fluxome to Evolva in November 2012. As a result of this historic tie with Denmark, Seventure is currently in late stage discussions with Scandinavian investors about joining the new €120 million Health for Life Capital Fund, which has already raised €73.5 million. The Health for Life Capital Fund aims to support innovative, high-growth entrepreneurial ventures primarily in Europe, but it also in North America and Asia. Investments are being made in the areas of healthcare, biotechnology and pharmaceuticals, connected health and medtech, nutrition and with a specific focus on the emerging game-changing field of microbiome.

- ENDS -

Contact:

At Seventure Partners	For media enquiries (Instinctif Partners):
Isabelle de Cremoux CEO/Managing Partners Tel: +33 6 77 05 4992 Email: isabelle.decremoux@seventure.fr	Melanie Toyne Sewell / Robert Mayer / Gemma Howe Tel: +44 20 7866 7860 Email: seventure@instinctif.com

Notes to Editors**About Seventure Partners**

Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure has invested in innovative businesses with high growth potential in digital technologies in France and Germany and in the life sciences field across Europe, with currently over €500m in assets under management.

In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology and cleantech, and the microbiome, lifestyle healthcare, personalised medicine and nutrition and food. Investments that can range between €500k and €10m per round, or up to €20m per company, from early to late stage, are also considered in the diagnostics. Seventure Partners also considers investments in the field of diagnostics, biomarkers, drug delivery systems, and services. Seventure is a subsidiary of Natixis, the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more information, please visit: www.seventure.fr

About Seventure Partners' Health for Life Capital Fund

In December 2013, Seventure launched its 'Health for Life Capital' Fund, the first venture capital fund focused on investment in high growth potential companies that provide innovative technologies or have the potential for disruptive innovation in the wider healthcare and the microbiome and nutrition space. Europe is the primary focus of the fund, but it will expand internationally if strategic opportunities arise. The €120m fund attracted strategic investments from prestigious organisations including Danone, Tereos, Tornier as well as financial institutions and is managed by Seventure's life sciences team.